Target Name: MUTYH
NCBI ID: G4595
Review Report on MUTYH Target / Biomarker Content of Review Report on MUTYH Target / Biomarker
MUTYH
Other Name(s): MYH | CYP2C | MUTYH variant 13 | MUTYH_HUMAN | mutY DNA glycosylase, transcript variant gamma4 | MUTYH variant gamma2 | OTTHUMP00000009101 | Adenine DNA glycosylase (isoform 1) | hMYH | MUTYH variant alpha5 | MutY DNA glycosylase, transcript variant alpha1 | MUTYH variant gamma3 | MutY DNA glycosylase, transcript variant alpha3 | MUTYH variant alpha1 | MUTYH variant alpha2 | MGC4416 | mutY DNA glycosylase | mutY DNA glycosylase, transcript variant 12 | OTTHUMP00000009099 | MutY DNA glycosylase, transcript variant alpha5 | A/G-specific adenine DNA glycosylase | MutY DNA glycosylase, transcript variant beta1 | MutY DNA glycosylase, transcript variant beta3 | MutY-like protein | MUTYH variant alpha3 | MutY (E. coli) homolog | OTTHUMP00000009098 | mutY DNA glycosylase, transcript variant alpha4 | HMYH | mutY DNA glycosylase, transcript variant gamma3 | MUTYH variant alpha4 | OTTHUMP00000009102 | OTTHUMP00000009097 | mutY homolog | MUTYH variant beta3 | mutY-like protein | MutY DNA glycosylase, transcript variant alpha2 | OTTHUMP00000009103 | Adenine DNA glycosylase | mutY DNA glycosylase, transcript variant 13 | MutY homolog | Adenine DNA glycosylase (isoform 8) | MUTYH variant beta1 | MUTYH variant gamma4 | Adenine DNA glycosylase (isoform 6) | MutY DNA glycosylase, transcript variant gamma2 | Adenine DNA glycosylase (isoform 7) | mutY DNA glycosylase, transcript variant beta5 | MUTYH variant beta5 | Adenine DNA glycosylase (isoform 5) | MUTYH variant 12 | OTTHUMP00000009096 | Adenine DNA glycosylase isoform 2 | Adenine DNA glycosylase (isoform 4) | OTTHUMP00000009100 | Adenine DNA glycosylase (isoform 3) | MutY homolog (MUTYH)

Understanding MUTYH: A Potential Drug Target Or Biomarker

MUTYH (Myeloid-derived suppressor protein) is a protein that is expressed in the myeloid cells of the bone marrow. It is a key regulator of the immune response and has been implicated in the development and progression of many diseases, including cancer. In recent years, researchers have been interested in exploring the potential of MUTYH as a drug target or biomarker.

The immune system is a critical component of the body's defense against infection and disease. The myeloid cells are a type of white blood cell that play a key role in the immune response by producing antibodies that help to fight off infections and viruses. MUTYH is one of the proteins that is expressed in the myeloid cells and is involved in regulating the immune response.

MUTYH has been shown to play a key role in the regulation of the immune response by controlling the activity of other immune cells. It has been shown to regulate the production of antibodies by myeloid cells and to control the movement of immune cells into the site of an infection or inflammation. MUTYH has also been shown to play a key role in the regulation of the immune response by controlling the production of regulatory T cells, which are a type of immune cell that help to maintain and regulate the activity of other immune cells.

In addition to its role in the immune response, MUTYH has also been shown to play a key role in the development and progression of many diseases, including cancer. For example, studies have shown that MUTYH is often expressed in tissues from patients with cancer and that it is involved in the regulation of the immune response at the tumor site. This suggests that MUTYH may be a useful biomarker for the diagnosis and treatment of cancer.

Despite these promising findings, much more research is needed to fully understand the role of MUTYH in the immune response and its potential as a drug target or biomarker. For example, it is not yet clear exactly how MUTYH functions as an immune system regulator or how it can be targeted by small molecules to induce its activity. Further research is needed to fully understand the role of MUTYH in the immune response and its potential as a drug target or biomarker.

Protein Name: MutY DNA Glycosylase

Functions: Involved in oxidative DNA damage repair. Initiates repair of A*oxoG to C*G by removing the inappropriately paired adenine base from the DNA backbone. Possesses both adenine and 2-OH-A DNA glycosylase activities

The "MUTYH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MUTYH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MVB12A | MVB12B | MVD | MVK | MVP | MX1 | MX2 | MXD1 | MXD3 | MXD4 | MXI1 | MXRA5 | MXRA5Y | MXRA7 | MXRA8 | MYADM | MYADML | MYADML2 | MYB | MYBBP1A | MYBL1 | MYBL2 | MYBPC1 | MYBPC2 | MYBPC3 | MYBPH | MYBPHL | MYC | MYCBP | MYCBP2 | MYCBP2-AS1 | MYCBPAP | MYCL | MYCL-AS1 | MYCLP1 | MYCN | MYCNOS | MYCNUT | MYCT1 | MYD88 | MYDGF | MYEF2 | Myelin Protein | MYEOV | MYF5 | MYF6 | MYG1 | MYH1 | MYH10 | MYH11 | MYH13 | MYH14 | MYH15 | MYH16 | MYH2 | MYH3 | MYH4 | MYH6 | MYH7 | MYH7B | MYH8 | MYH9 | MYHAS | MYL1 | MYL10 | MYL11 | MYL12A | MYL12B | MYL12BP3 | MYL2 | MYL3 | MYL4 | MYL5 | MYL6 | MYL6B | MYL7 | MYL9 | MYLIP | MYLK | MYLK-AS1 | MYLK-AS2 | MYLK2 | MYLK3 | MYLK4 | MYLKP1 | MYMK | MYMX | MYNN | MYO10 | MYO15A | MYO15B | MYO16 | MYO16-AS1 | MYO16-AS2 | MYO18A | MYO18B | MYO19 | MYO1A | MYO1B | MYO1C